Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 4/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.46 |
| ▸ | MEN1 | O00255 | 5/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | BCHE | P06276 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | LTA4H | P09960 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2900357 | 0.80 | HTT (0.58) | HTTLMNASMN1; SMN2NPSR1ALDH1A1 | |
| SCHEMBL1279045 | 0.75 | HTT (0.73) | HTTSMN1; SMN2ALDH1A1KDM4EKMT2A | |
| SCHEMBL11669811 | 0.73 | HTT (0.51) | HTTLMNASMN1; SMN2NPSR1ALDH1A1 | |
| SCHEMBL2182266 | 0.73 | HTT (0.71) | HTTLMNASMN1; SMN2NPSR1ALDH1A1 | |
| SCHEMBL16072940 | 0.72 | CHRM2 (0.58) | HTTLMNASMN1; SMN2NPSR1ALDH1A1 | |
| SCHEMBL13886625 | 0.71 | KDM4E (0.51) | HTTLMNASMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL29821835 | 0.71 | KMT2A (0.43) | HTTLMNASMN1; SMN2KDM4EKMT2A | |
| SCHEMBL23160258 | 0.69 | LMNA (0.61) | HTTLMNASMN1; SMN2NPSR1ALDH1A1 | |
| SCHEMBL812875 | 0.69 | CYP2C19 (0.48) | ALDH1A1KMT2A | |
| SCHEMBL15011685 | 0.69 | MEN1 (0.48) | HTTLMNASMN1; SMN2KDM4EKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7078565-B2 | Benzamide derivatives as antagonists of orexin receptors | SMITHKLINE BEECHAM PLC (GB) | 2006-07-18 | — | — | US | disclosed |
| US-20050020584-A1 | Benzamide derivatives as antagonists of orexin receptors | SMITHKLINE BEECHAM P.L.C. (GB) | 2005-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050020584-A1 | Benzamide derivatives as antagonists of orexin receptors | HCRTR2, HCRTR1, OXTR | HTT 481/4885LMNA 3250/4885SMN1; SMN2 3217/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.